News

ONCOBIOME, 1st consortium about microbiome & cancer, led by Gustave Roussy

Published on

Changed on

Gustave Roussy, leading European Cancer Centre, is collaborating with 16 international partners in the Oncobiome consortium. The objective of the programme is to determine the relationship between intestinal microbial signatures (GOMS) and the incidence, prognosis and resistance to treatment (and toxicity of this) in cancers of breast, colon, lung and melanoma. .

Gustave Roussy, one of 18 Cancer Centres and member of Unicancer, was chosen for its Oncobiome project by the European Commission as a result of the tendering process for project SC1-BHC-03-2018, “Exploitation of research results and the potential for application of the human microbiome in prediction, prevention and personalised treatment of disease”.    

The Oncobiome research units seek to confirm the link between cancer and intestinal microbiota and to show that the efficacy of treatment depends on specific features of the intestinal microbiome. It is already recognised that the intestinal metagenome is involved in the regulation of multiple physiological functions with effects on health. It is implicated in the initiation and progression of cancer and in response to treatment even in extra-intestinal neoplasia.   

“There is an urgent need to identify and characterise the commensal ecosystem minimalism related to cancer using robust, reliable techniques; to define the intestinal microbiome signatures associated with cancer; and to develop diagnostic tools which will become a part of the oncological arsenal to optimise and personalise treatment,”  explains Professor Laurence Zitvogel, scientific director of the Gustave Roussy immunotherapy programme, director of the Inserm U1015 Unit, RHU Lumiére prizewinner financed by the National Research Agency, and coordinator of Oncobiome.

The Oncobiome project will thus embark on an analysis of the data from more than 9,000 cancer patients in 8 countries (Germany, England, Canada, France, Italy, the Netherlands, the Czech Republic and Sweden) employing retrospective and prospective studies in four common cancers: breast, colorectal, lung and melanoma.  

About Oncobiome

The project commenced officially on 1st January 2019, and was launched with all the collaborators on 4th February 2019. It will run for 5 years. It is supported by the European Commission with a grant of 15 million euros. The following French units are participating:

The other internationals collaborators are:

Last news

  • Two photon-counting CT scanners now equip Gustave Roussy's imaging department

    Since September 2026, Gustave Roussy's Department of Medical Imaging has been equipped with a second photon-counting CT scanner, delivering higher image resolution while reducing the doses of X-rays and contrast agent administered to patients. This technology recently enabled the Institute to perform an iodine-free pulmonary CT angiogram, a world first.

    Photographie du scanner à comptage photonique
  • Prevention and screening: getting ahead of lung cancer

    To mark Thoracic Cancer Awareness Month and Tobacco-Free Month, two campaigns focusing on lung cancer, Gustave Roussy highlights its initiatives to advance prevention and screening among people at increased risk. Since its creation in 2021, the Institute’s Interception Lung programme has welcomed more than 900 participants, supporting them to stop smoking and offering personalised screening for the disease.

    Photographie : patient effectuant un scanner thoracique et équipes soignantes
  • Gustave Roussy Meets His Audience

    As part of its awareness-raising and fundraising efforts, Gustave Roussy is currently conducting a door-to-door outreach campaign in several towns in Val-de-Marne (Fresnes, Vitry-sur-Seine, Nogent-sur-Marne, Bry-sur-Marne, Le Kremlin-Bicêtre) from Monday through Saturday, 1:30 p.m. to 8:00 p.m.

    Deux personnes en charge de la collecte porte-à-porte
  • Mens November: Take care of your jewelry its precious!

    November is the month dedicated to raising awareness and promoting prevention of male cancers, which include prostate, testicular, and penile cancers. The goal is to raise public awareness of these diseases—which account for approximately 63,000 new cases in France each year—and to encourage men to perform testicular self-exams, a simple step that can help detect a lump, the nature of which must then be determined through further medical examinations. Gustave Roussy has extensive expertise in the treatment of male cancers, particularly through its Genitourinary Oncology Committee, which is deeply involved in research on these diseases. 

    Visuel fixe campagne novembre masculin